EMA approvals

Market Access

The EMA is implementing major changes to accelerate drug approvals in the EU, addressing delays that affect patients and businesses alike

Market Access

The FDA released its overview of 2023 and the drugs it had approved during the year.

Oncology

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.